Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00865852 · ClinicalTrials.gov registry record · Phase 1

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

A Phase 1 study, sponsored by Actavis.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT00865852: Completed Phase 1 study, sponsored by Actavis.

NCT00865852 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00865852, a Phase 1 study, has completed, sponsored by Actavis.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 750 mg) in healthy adult volunteers under non-fasting conditions

Interventions

  • DRUG Metformin HCl 750 mg Extender Release tablets, single dose
  • DRUG GLUCOPHAGE® XR 750 mg tablets, single dose

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2003-08
Est. Completion 2003-08
Phase Phase 1
Actavis

79 total trials

What the finished NCT00865852 record still lists

NCT00865852 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 2 interventions - of which Metformin HCl 750 mg Extender Release tablets, single dose is the first listed.

NCT00865852 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00865852 about?

NCT00865852 is a clinical study titled "A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions". The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 750 mg) in healthy adult volunteers u...

What is the current status of trial NCT00865852?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2003-08. Estimated completion is 2003-08.

What interventions are being tested in trial NCT00865852?

The interventions under investigation include: Metformin HCl 750 mg Extender Release tablets, single dose (DRUG), GLUCOPHAGE® XR 750 mg tablets, single dose (DRUG).

Who is sponsoring clinical trial NCT00865852?

This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00865852's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00865852, the US trial registry maintained by the National Library of Medicine. NCT00865852 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.